First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report

ABSTRACT Background Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR‐tyrosine kinase inhibitors are generally less effective for EGFR‐mutated squamous cell lung carcinoma. We herein present a case of EGFR‐mutated squamous cell lung carcinoma that respo...

Full description

Bibliographic Details

Published in:	Cancer Reports
Main Authors:	Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Tacheuchi
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Subjects:	EGFR mutation EGFR‐TKI L858R osimertinib squamous cell lung cancer
Online Access:	https://doi.org/10.1002/cnr2.70273